Literature DB >> 25776029

Immunohistochemical expression of ARID1A in penile squamous cell carcinomas: a tissue microarray study of 112 cases.

Sheila F Faraj1, Alcides Chaux2, Nilda Gonzalez-Roibon1, Enrico Munari1, Antonio L Cubilla3, Ie-Ming Shih1, George J Netto4.   

Abstract

ARID1A, a member of the chromatin remodeling genes family, has been suggested as a novel tumor suppressor gene in gynecologic malignancies. However, its role in penile cancer has yet to be determined. This study assesses the immunohistochemical expression of ARID1A in penile squamous cell carcinoma (SCC) and its association with pathologic features, human papillomavirus (HPV) status, and previously reported mammalian target of rapamycin pathway markers in the same cohort. Four tissue microarrays were constructed from 112 cases of formalin-fixed, paraffin-embedded penile SCC from Paraguay. Each tumor was sampled 3 to 12 times. ARID1A expression was evaluated by immunohistochemistry using a polyclonal rabbit anti-ARID1A (BAF250A) antibody. An H score was calculated in each spot as the sum of expression intensity (0-3+) by extent (0%-100%). Median H score per case was used for statistical analysis. ARID1A expression was observed in all cases, ranging from 3% to 100% of tumor cells (median, 95%). In 96 cases (86%), ARID1A expression was observed in 90% or more tumor cells. HPV DNA was detected in 20 (38%) of 52 analyzed samples. There was a significant trend of association between ARID1A and histologic grade. ARID1A expression was not associated with histologic subtype (P = .61) or HPV status (P = .18). ARID1A expression decreased with decreasing levels of PTEN expression (P = .01). ARID1A was expressed in penile SCC, in most cases at high levels. A significant trend of association was found between histologic grade and ARID1A expression, with lower ARID1A expression, lower histologic grades, and decreased PTEN expression.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  ARID1A; BAF250A; Penile SCC; SWI/SNF; mTOR pathway

Mesh:

Substances:

Year:  2015        PMID: 25776029      PMCID: PMC4696050          DOI: 10.1016/j.humpath.2015.01.018

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  32 in total

1.  Frequent loss of tumor suppressor ARID1A protein expression in adenocarcinomas/adenosquamous carcinomas of the uterine cervix.

Authors:  Atsuko Katagiri; Kentaro Nakayama; Mohammed Tanjimur Rahman; Munmun Rahman; Hiroshi Katagiri; Masako Ishikawa; Tomoka Ishibashi; Kouji Iida; Yoshiro Otsuki; Satoru Nakayama; Kohji Miyazaki
Journal:  Int J Gynecol Cancer       Date:  2012-02       Impact factor: 3.437

Review 2.  A decade of tissue microarrays: progress in the discovery and validation of cancer biomarkers.

Authors:  Robert L Camp; Veronique Neumeister; David L Rimm
Journal:  J Clin Oncol       Date:  2008-10-20       Impact factor: 44.544

3.  Immunoexpression status and prognostic value of mTOR and hypoxia-induced pathway members in primary and metastatic clear cell renal cell carcinomas.

Authors:  Luciana Schultz; Alcides Chaux; Roula Albadine; Jessica Hicks; Jenny J Kim; Angelo M De Marzo; Mohamad E Allaf; Michael A Carducci; Ronald Rodriguez; Hans-Joerg Hammers; Pedram Argani; Victor E Reuter; George J Netto
Journal:  Am J Surg Pathol       Date:  2011-10       Impact factor: 6.394

4.  Mutation and loss of expression of ARID1A in uterine low-grade endometrioid carcinoma.

Authors:  Bin Guan; Tsui-Lien Mao; Pradeep K Panuganti; Elisabetta Kuhn; Robert J Kurman; Daichi Maeda; Elizabeth Chen; Yung-Ming Jeng; Tian-Li Wang; Ie-Ming Shih
Journal:  Am J Surg Pathol       Date:  2011-05       Impact factor: 6.394

Review 5.  Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer--shifting the paradigm.

Authors:  Robert J Kurman; Ie-Ming Shih
Journal:  Hum Pathol       Date:  2011-07       Impact factor: 3.466

Review 6.  Developments in the pathology of penile squamous cell carcinomas.

Authors:  Alcides Chaux; Elsa F Velazquez; Ferran Algaba; Gustavo Ayala; Antonio L Cubilla
Journal:  Urology       Date:  2010-08       Impact factor: 2.649

7.  p53 as a new prognostic factor for lymph node metastasis in penile carcinoma: analysis of 82 patients treated with amputation and bilateral lymphadenectomy.

Authors:  Ademar Lopes; Artur Licio R Bezerra; Clovis Antonio Lopes Pinto; Sergio Vicente Serrano; Celso Abdon de MellO; Luisa Lina Villa
Journal:  J Urol       Date:  2002-07       Impact factor: 7.450

8.  A phase II multicentre study of irinotecan (CPT 11) in combination with cisplatin (CDDP) in metastatic or locally advanced penile carcinoma (EORTC PROTOCOL 30992).

Authors:  C Theodore; I Skoneczna; I Bodrogi; M Leahy; J M Kerst; L Collette; K Ven; S Marréaud; R D T Oliver
Journal:  Ann Oncol       Date:  2008-04-15       Impact factor: 32.976

9.  Somatic mutations in the chromatin remodeling gene ARID1A occur in several tumor types.

Authors:  Siân Jones; Meng Li; D Williams Parsons; Xiaosong Zhang; Jelle Wesseling; Petra Kristel; Marjanka K Schmidt; Sanford Markowitz; Hai Yan; Darell Bigner; Ralph H Hruban; James R Eshleman; Christine A Iacobuzio-Donahue; Michael Goggins; Anirban Maitra; Sami N Malek; Steve Powell; Bert Vogelstein; Kenneth W Kinzler; Victor E Velculescu; Nickolas Papadopoulos
Journal:  Hum Mutat       Date:  2011-11-23       Impact factor: 4.878

10.  A functional proteogenomic analysis of endometrioid and clear cell carcinomas using reverse phase protein array and mutation analysis: protein expression is histotype-specific and loss of ARID1A/BAF250a is associated with AKT phosphorylation.

Authors:  Kimberly C Wiegand; Bryan T Hennessy; Samuel Leung; Yemin Wang; Zhenlin Ju; Mollianne McGahren; Steve E Kalloger; Sarah Finlayson; Katherine Stemke-Hale; Yiling Lu; Fan Zhang; Michael S Anglesio; Blake Gilks; Gordon B Mills; David G Huntsman; Mark S Carey
Journal:  BMC Cancer       Date:  2014-02-22       Impact factor: 4.430

View more
  4 in total

1.  Matrix metalloproteinase-12 expression is increased in cutaneous melanoma and associated with tumor aggressiveness.

Authors:  Zixi Zhang; Shaojun Zhu; Yang Yang; Xianjie Ma; Shuzhong Guo
Journal:  Tumour Biol       Date:  2015-06-04

2.  Comprehensive Genomic Profiling of Advanced Penile Carcinoma Suggests a High Frequency of Clinically Relevant Genomic Alterations.

Authors:  Siraj M Ali; Sumanta K Pal; Kai Wang; Norma A Palma; Eric Sanford; Mark Bailey; Jie He; Julia A Elvin; Juliann Chmielecki; Rachel Squillace; Edward Dow; Deborah Morosini; Jamie Buell; Roman Yelensky; Doron Lipson; Garrett M Frampton; Peter Howley; Jeffrey S Ross; Philip J Stephens; Vincent A Miller
Journal:  Oncologist       Date:  2015-12-15

3.  Impact of PI3K-AKT-mTOR Signaling Pathway Up-regulation on Prognosis of Penile Squamous-Cell Carcinoma: Results From a Tissue Microarray Study and Review of the Literature.

Authors:  Mounsif Azizi; Dominic H Tang; Daniel Verduzco; Charles C Peyton; Juan Chipollini; Zhigang Yuan; Braydon J Schaible; Jun-Min Zhou; Peter A Johnstone; Anna Giuliano; Jasreman Dhillon; Philippe E Spiess
Journal:  Clin Genitourin Cancer       Date:  2018-09-22       Impact factor: 3.121

4.  Aberrant CEACAM19 expression is associated with metastatic phenotype in penile cancer.

Authors:  Xiheng Hu; Mingfeng Chen; Yangle Li; Yin Wang; Sailan Wen; Fu Jun
Journal:  Cancer Manag Res       Date:  2019-01-14       Impact factor: 3.989

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.